Summit Therapeutics (SMMT, Financial) has made noteworthy advancements in the oncology sector, particularly with its lead therapy, ivonescimab. The drug has garnered regulatory approval in China for the treatment of PD-L1 positive non-small cell lung cancer, marking a crucial milestone for the company. Moving forward, Summit is geared up to initiate global Phase III HARMONi trials focused on EGFR-mutated advanced NSCLC, with outcomes anticipated by mid-2025.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.